Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.

Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.

Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.

Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The disclosed agonist antibody comprises (1) antibody constant regions comprising heavy and light chain constant regions, each of which may optionally contain domain substitutions, or may contain deletions, substitutions, additions, or insertions of amino acid residues, and (2) antibody variable regions capable of binding to and activating a human thrombopoietin receptor. The-agonist antibody further induces colony formation at a concentration of 10,000 ng/ml or lower, and has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less.

Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl).

Abstract: This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl).

Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.

Abstract: The invention relates to a method for activating human-derived antigen-presenting cells by in vitro cultivation with at least one of the glycoside compounds represented by formula (A) or salts thereof [preferred example: (2S,3S,4R)-1-(?-D-galactopyranosyloxy)-2-hexacosanoylamino-3,4-octadecanediol], and to human antigen-presenting cells activated by the method. The invention also relates to a method for treatment of cancer and infectious diseases including AIDS with the activated human antigen-presenting cells, and to a use of the activated human antigen-presenting cells in the preparation of medicines for treating such diseases. The invention can provide a satisfactory therapeutic effect on cancer and infectious diseases including AIDS without the need to pulse the human antigen-presenting cells with tumor antigens.

Abstract: Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing human hepatocyte toxicity, and an anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having the following properties: having activity to induce apoptosis in carcinoma cells independently of exogenous factors and as a monomer of an antibody.

Abstract: A composition for enhancing immunogenicity of tumor cells or pathogen-infected cells comprising a compound having an &agr;-glycosylceramide structure or a salt or solvate thereof is provided. Tumor cells of which immunogenicity is enhanced by the compound having an &agr;-glycosylceramide structure are useful for tumor therapy (cancer vaccine therapy).

Abstract: The present invention relates to a method for the treatment of thrombocytopenia wherein an effective amount of a compound represented by the formula (A) is administered to a patient: wherein R.sub.2 represents H or OH, X is an integer of 0-26 or R represents --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1 is a substituent defined by the following (a) to (d):(a) --CH.sub.2 (CH.sub.2).sub.y CH.sub.3,(b) --CH(OH)(CH.sub.2).sub.y CH.sub.3,(c) --CH(OH)(CH.sub.2).sub.y CH(CH.sub.3).sub.2, or(d) --CH.dbd.(CH)(CH.sub.2).sub.y CH.sub.3wherein Y is an integer of 5-17.

Abstract: The present invention relates to a pharmaceutical composition (a marrow cell proliferation accelerator, a radioprotective agent, a therapeutic agent for thrombocytopenia) comprising a compound represented by the following formula (A), and to a therapeutic or prophylactic method (a method for accelerating marrow cell proliferation, a method for protecting human against radiation damage, a method for the treatment of thrombocytopenia) characterized in that an effective amount of a compound represented by the following formula (A) is administered to human: ##STR1## wherein R represents ##STR2## (wherein R.sub.2 represents H or OH, X is an integer of 0-26) or --(CH.sub.2).sub.7 CH.dbd.CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1 is one of the substituents defined by the following (a) to (d):--CH.sub.2 (CH.sub.2).sub.Y CH.sub.3, (a)--CH(OH)(CH.sub.2).sub.Y CH.sub.3, (b)--CH(OH)(CH.sub.2).sub.Y CH(CH.sub.3).sub.2, (c)and--CH.dbd.CH(CH.sub.2).sub.Y CH.sub.3 (d)(wherein Y is an integer of 5-17).

Abstract: The present invention relates to a sphingoglycolipid represented by the formula (I): ##STR1## wherein R.sub.1, R.sub.2 and R.sub.5 represent H or a specific monosaccharide; R.sub.3 and R.sub.6 represent H or OH, respectively;R.sub.4 represents H, OH or a specific monosaccharide;X denotes an integer from 19 to 23;R.sub.7 represents any one of the following groups (a)-(g):(a) --(CH.sub.2).sub.11 --CH.sub.3,(b) --(CH.sub.2).sub.12 --CH.sub.3,(c) --(CH.sub.2).sub.13 --CH.sub.3,(d) --(CH.sub.2).sub.9 --CH(CH.sub.3).sub.2,(e) --(CH.sub.2).sub.10 --CH(CH.sub.3).sub.2,(f) --(CH.sub.2).sub.11 --CH(CH.sub.3).sub.2,(g) --(CH.sub.2).sub.11 --CH(CH.sub.3)--C.sub.2 H.sub.5.

Abstract: The present invention relates to a pharmaceutical composition (a marrow cell proliferation accelerator, a radioprotective agent, a therapeutic agent for thrombocytopenia) comprising a compound represented by the following formula (A), and to a therapeutic or prophylactic method (a method for accelerating marrow cell proliferation, a method for protecting human against radiation damage, a method for the treatment of thrombocytopenia) characterized in that an effective amount of a compound represented by the following formula (A) is administered to human: ##STR1## wherein R.sub.2 represents ##STR2## 26) or --(CH.sub.2).sub.7 CH=CH(CH.sub.2).sub.7 CH.sub.3, and R.sub.1, is one of the substituents defined by the following (a) to (d):(a) --CH.sub.2 (CH.sub.2).sub.y CH.sub.3,(b) --CH(OH)(CH.sub.2).sub.y (CH.sub.3).sub.2, and(c) --CH(OH)(CH.sub.2).sub.y CH(CH.sub.3).sub.2, and(d) --CH=CH(CH.sub.2).sub.y CH.sub.3(wherein Y is an integer of 5-17).